AbbVie Advances Oncology Pipeline With Start of Multiple Myeloma …
Jun 5, 2024 · ABBV-383 is a B-cell maturation antigen (BCMA) bispecific antibody T-cell engager being evaluated in relapsed/refractory multiple myeloma (r/r MM) The CERVINO Phase 3 trial will evaluate the efficacy, safety, and tolerability of ABBV-383 monotherapy compared with standard available therapies (SATs) in patients with r/r MM who have received at ...
AbbVie and Simcere Zaiming Announce Partnership to Develop a …
5 days ago · NORTH CHICAGO, Ill. and SHANGHAI, Jan. 13, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) today announced an option to license agreement to develop SIM0500, an investigational new drug candidate. SIM0500 is currently in Phase 1 clinical trials in patients with relapsed or refractory multiple myeloma (MM), in both ...
AbbVie Presents Results from Phase 3 CANOVA Study of …
Sep 29, 2023 · CANOVA study evaluated venetoclax plus dexamethasone in patients with t(11;14)-positive multiple myeloma compared to pomalidomide plus dexamethasone; Results are being presented at the International Myeloma Society Annual Meeting in Athens, Greece
MULTIPLE MYELOMA (MM) - abbviescience.com
MM is most frequently diagnosed among people aged 65 to 74 years. The median age at diagnosis is 69 years. MM is typically defined as "a clonal plasma cell malignant neoplasm." In reality, it is a collection of several different cytogenetically distinct …
AbbVie Advances Oncology Pipeline With Start of Multiple Myeloma …
Jun 5, 2024 · ABBV-383 is a B-cell maturation antigen (BCMA) bispecific antibody T-cell engager being evaluated in relapsed/refractory multiple myeloma (r/r MM)
Phase III CANOVA Trial of Venetoclax | Int'l Myeloma Foundation
Oct 3, 2023 · AbbVie has announced data from its Phase III CANOVA study, which evaluated the safety and efficacy of venetoclax plus dexamethasone for patients with t(11;14)-positive relapsed or refractory multiple myeloma. The results did not show a significant improvement in progression-free survival compared to pomalidomide plus dexamethasone.
First R/R Myeloma Patient Receives ABBV-383 - HealthTree
Jun 21, 2024 · AbbVie announced on June 5, 2024, that the first relapsed/refractory myeloma patient in their phase 3 study started treatment with the new BCMA-directed bispecific antibody called ABBV-383.
Simcere Zaiming and AbbVie Announce Partnership to
5 days ago · "As a leader in hematologic malignancies, AbbVie is committed to advancing innovative treatments for complex cancers like multiple myeloma through our relentless R&D efforts and collaborations ...
Paper: Updated Safety and Efficacy Results of Abbv-383, a BCMA x …
ABBV-383 is an off-the-shelf, fully human B-cell maturation antigen (BMCA) X CD3 bispecific antibody with bivalent BCMA domain and low CD3 affinity that targets both BCMA-expressing multiple myeloma (MM) cells and CD3-expressing T cells.
AbbVie treats first subject in Phase III multiple myeloma trial
Jun 6, 2024 · ABBV-383 is a bispecific antibody T-cell engager that binds to both BCMA and CD3, designed to target and engage T-cells to fight cancer cells. The multi-centre, open-label, randomised, global trial is designed to assess ABBV-383 against standard available therapies.